Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.

Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status

Open access

Abstract

The efficacy of standard antidepressants is limited for many patients with mood disorders such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent need to develop novel therapeutics. Both clinical and preclinical studies have implicated glutamatergic system dysfunction in the pathophysiology of mood disorders. In particular, rapid reductions in depressive symptoms have been observed in response to subanesthetic doses of the glutamatergic modulator racemic (R,S)-ketamine in individuals with mood disorders. These results have prompted investigation into other glutamatergic modulators for depression, both as monotherapy and adjunctively. Several glutamate receptor-modulating agents have been tested in proof-of-concept studies for mood disorders. This manuscript gives a brief overview of the glutamate system and its relevance to rapid antidepressant response and discusses the existing clinical evidence for glutamate receptor-modulating agents, including (1) broad glutamatergic modulators ((R,S)-ketamine, esketamine, (R)-ketamine, (2R,6R)-hydroxynorketamine [HNK], dextromethorphan, Nuedexta [a combination of dextromethorphan and quinidine], deudextromethorphan [AVP-786], axsome [AXS-05], dextromethadone [REL-1017], nitrous oxide, AZD6765, CLE100, AGN-241751); (2) glycine site modulators (D-cycloserine [DCS], NRX-101, rapastinel [GLYX-13], apimostinel [NRX-1074], sarcosine, 4-chlorokynurenine [4-Cl-KYN/AV-101]); (3) subunit (NR2B)-specific N-methyl-D-aspartate (NMDA) receptor antagonists (eliprodil [EVT-101], traxoprodil [CP-101,606], rislenemdaz [MK-0657/CERC-301]); (4) metabotropic glutamate receptor (mGluR) modulators (basimglurant, AZD2066, RG1578, TS-161); and (5) mammalian target of rapamycin complex 1 (mTORC1) activators (NV-5138). Many of these agents are still in the preliminary stages of development. Furthermore, to date, most have demonstrated relatively modest effects compared with (R,S)-ketamine and esketamine, though some have shown more favorable characteristics. Of these novel agents, the most promising, and the ones for which the most evidence exists, appear to be those targeting ionotropic glutamate receptors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40263-021-00816-x

Cites

127 of 127 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 127 references

Research works printed but not linked: 3

  1. NeuroRx. NeuroRx: Phase 3 drug for suicidal bipolar depression to present at BIO CEO conference. February 10, 2020. 2020. https://www.prnewswire.com/news-releases/neurorx-phase-3-drug-for-suicidal-bipolar-depression-to-present-at-bio-ceo-conference-301001882.html. Accessed 12 Aug 2020.
  2. Paterson B, Fraser H, Wang C, Marcus R. A randomized, double-blind, placebo-controlled, sequential parallel study of CERC-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment. National Network of Depression Centers Annual Conference; 2015 November 5-6; Ann Arbor, Michigan; 2015. http://c.eqcdn.com/_2a1b537df6a6e1398b6806c9b30635ad/cerecor/db/322/603/file/Poster+-+Study+Clin301-201_FINAL.pdf. Accessed 12 June 2020.
  3. Sage Therapeutics. Sage announces pivotal Phase 3 trial status for SAGE-217 in major depressive disorder and postpartum depression based on FDA breakthrough therapy meeting. 2018. https://investor.sagerx.com/news-releases/news-release-details/sage-announces-pivotal-phase-3-trial-status-sage-217-major. Accessed 12 June 2020.

Cited by

See all 161

Metadata

Authors
Henter, I. D., Park, L. T., & Zarate, C. A.
Affiliations
National Institutes of Health (US)
Corresponding author
Zarate, Carlos A.
Venue
CNS Drugs
Published
2021-04-26
Volume
35
Issue
5
Pages
527-543
ISSN
  • 1172-7047 (ISSN-L)
  • 1179-1934
OpenAlex
W3157093408
Cited by
142
References
127
Citations by year
2026: 19 · 2025: 20 · 2024: 34 · 2023: 28 · 2022: 29 · 2021: 12
FWCI
3.29
Type
journal article
Language
en
Open access
Licence
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Mental Health (ZIAMH002857)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
mood disorders, major depressive disorder, bipolar depression, ketamine, esketamine, hydroxynorketamine, dextromethorphan, D-cycloserine, NMDA receptor antagonists, rapid antidepressant response, antidepressant resistance
MeSH terms
Animals, Antidepressive Agents, Bipolar Disorder, Major Depressive Disorder, Humans, Receptors, Glutamate, Excitatory Amino Acid Agents, Glutamic Acid, Mood Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status. https://app.cochat.ai/papers/10.1007/s40263-021-00816-x
The paper
Henter, I. D., Park, L. T., & Zarate, C. A. (2021). Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status. CNS Drugs. https://doi.org/10.1007/s40263-021-00816-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.